We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Inspira Technologies (IINN) Releases Favorable Data on VORTX
Read MoreHide Full Article
Inspira Technologies OXY B.H.N. Ltd. (IINN - Free Report) has achieved a significant milestone with its orbiting blood oxygenation technology, VORTX. The company announced achieving 100% compliance with regulatory guidelines for blood oxygenation and carbon dioxide removal with VORTX.
This achievement holds promise for the field of orbiting oxygenation technology, supplanting traditional mechanical ventilators with a superior alternative.
Technological Advancement
The recent announcement by Inspira Technologies highlights the successful adherence to regulatory guidelines for blood oxygenation and carbon dioxide removal while maintaining a zero-level pressure gradient across the device. This feat is crucial as it mitigates high mechanical shear stress, which can cause significant damage to blood components.
Inspira Technologies’ proprietary orbiting oxygenation technology eliminates the need for membrane fibers, thereby reducing pressure differentials and high shear stress. This development marks a pivotal moment in advancing patient care and mitigating critical clinical complications associated with traditional oxygenation devices.
Performance and Scalability
Advanced experiments showcasing VORTX’s performance demonstrate exceptional oxygenation and carbon dioxide removal capabilities, with minimal to zero pressure even at higher flow rates. This contrasts sharply with membrane-based devices, which often experience substantial pressure drops, posing risks to patients.
Image Source: Zacks Investment Research
Future Implications
Inspira Technologies' achievement with VORTX signals a shift away from fiber membrane-based devices toward a technology that offers superior gas exchange without associated complications. Moreover, transitioning to alternative materials will reduce manufacturing costs and lessen dependency on a single raw material supplier, ensuring sustainability and accessibility in the long term.
Growing Market Prospects
According to a Verified Market Research report, the global Extracorporeal Membrane Oxygenation machine market is poised for substantial growth. It is projected to touch $876.17 million by 2030 from $529.74 in 2021, at a CAGR of 5.8%, primarily driven by the increasing prevalence of cardiopulmonary illnesses and respiratory failures. This growth will be further fueled by advancements in system development, including the introduction of oxygenators, hollow pumps and heparin-coated cannulas.
Factors such as rising disease incidence, an aging population, favorable legislative changes and investment opportunities are also contributing to market expansion. Despite obstacles like higher costs and equipment issues, technological progress and government funding continue to propel market growth.
Share Price Performance
Over the past year, shares of IINN have risen 25% compared with the industry’s 10.7% growth.
Zacks Rank and Key Picks
Inspira Technologies currently carries a Zacks Rank #3 (Hold).
Estimates for DaVita’s 2024 earnings per share have moved from $8.46 to $8.97 in the past 30 days. Shares of the company have surged 81.9% in the past year compared with the industry’s 26.9% rise.
DVA’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 35.57%. In the last reported quarter, it delivered an earnings surprise of 22.22%.
Cardinal Health’s stock has surged 59.1% in the past year. Earnings estimates for Cardinal Health have risen from $7.17 to $7.28 for fiscal 2024 and from $7.94 to $8.03 for fiscal 2025 in the past 30 days.
CAH’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 15.6%. In the last reported quarter, it posted an earnings surprise of 16.67%.
Estimates for Stryker’s 2024 earnings per share have increased from $11.84 to $11.86 in the past 30 days. Shares of the company have moved 30.7% upward in the past year compared with the industry’s rise of 10.8%.
SYK’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.09%. In the last reported quarter, it delivered an earnings surprise of 5.81%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Inspira Technologies (IINN) Releases Favorable Data on VORTX
Inspira Technologies OXY B.H.N. Ltd. (IINN - Free Report) has achieved a significant milestone with its orbiting blood oxygenation technology, VORTX. The company announced achieving 100% compliance with regulatory guidelines for blood oxygenation and carbon dioxide removal with VORTX.
This achievement holds promise for the field of orbiting oxygenation technology, supplanting traditional mechanical ventilators with a superior alternative.
Technological Advancement
The recent announcement by Inspira Technologies highlights the successful adherence to regulatory guidelines for blood oxygenation and carbon dioxide removal while maintaining a zero-level pressure gradient across the device. This feat is crucial as it mitigates high mechanical shear stress, which can cause significant damage to blood components.
Inspira Technologies’ proprietary orbiting oxygenation technology eliminates the need for membrane fibers, thereby reducing pressure differentials and high shear stress. This development marks a pivotal moment in advancing patient care and mitigating critical clinical complications associated with traditional oxygenation devices.
Performance and Scalability
Advanced experiments showcasing VORTX’s performance demonstrate exceptional oxygenation and carbon dioxide removal capabilities, with minimal to zero pressure even at higher flow rates. This contrasts sharply with membrane-based devices, which often experience substantial pressure drops, posing risks to patients.
Image Source: Zacks Investment Research
Future Implications
Inspira Technologies' achievement with VORTX signals a shift away from fiber membrane-based devices toward a technology that offers superior gas exchange without associated complications. Moreover, transitioning to alternative materials will reduce manufacturing costs and lessen dependency on a single raw material supplier, ensuring sustainability and accessibility in the long term.
Growing Market Prospects
According to a Verified Market Research report, the global Extracorporeal Membrane Oxygenation machine market is poised for substantial growth. It is projected to touch $876.17 million by 2030 from $529.74 in 2021, at a CAGR of 5.8%, primarily driven by the increasing prevalence of cardiopulmonary illnesses and respiratory failures. This growth will be further fueled by advancements in system development, including the introduction of oxygenators, hollow pumps and heparin-coated cannulas.
Factors such as rising disease incidence, an aging population, favorable legislative changes and investment opportunities are also contributing to market expansion. Despite obstacles like higher costs and equipment issues, technological progress and government funding continue to propel market growth.
Share Price Performance
Over the past year, shares of IINN have risen 25% compared with the industry’s 10.7% growth.
Zacks Rank and Key Picks
Inspira Technologies currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are DaVita (DVA - Free Report) , Cardinal Health (CAH - Free Report) and Stryker (SYK - Free Report) . While DaVita sports a Zacks Rank #1 (Strong Buy), Cardinal Health and Stryker carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for DaVita’s 2024 earnings per share have moved from $8.46 to $8.97 in the past 30 days. Shares of the company have surged 81.9% in the past year compared with the industry’s 26.9% rise.
DVA’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 35.57%. In the last reported quarter, it delivered an earnings surprise of 22.22%.
Cardinal Health’s stock has surged 59.1% in the past year. Earnings estimates for Cardinal Health have risen from $7.17 to $7.28 for fiscal 2024 and from $7.94 to $8.03 for fiscal 2025 in the past 30 days.
CAH’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 15.6%. In the last reported quarter, it posted an earnings surprise of 16.67%.
Estimates for Stryker’s 2024 earnings per share have increased from $11.84 to $11.86 in the past 30 days. Shares of the company have moved 30.7% upward in the past year compared with the industry’s rise of 10.8%.
SYK’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.09%. In the last reported quarter, it delivered an earnings surprise of 5.81%.